Loading data for ALDX — first visit, this takes a few seconds.

アラート

Aldeyra Therapeutics Inc. (ALDX)

NasdaqCM: ALDX · リアルタイム株価 · USD

1.58

+0.03 (1.94%)

終値時点： Aug 20, 2026, 1:25 PM

1.94% (1D)

買気配	1.15
時価総額	92M
売上高（TTM）	n/a
純利益（TTM）	-23.05M
ベータ	1.20
EPS（TTM）	-0.38
PER（TTM）	n/a
予想PER	-5.55
PBR（TTM）	2.43
PSR（TTM）	n/a
Earnings Date	Nov 4, 2026

売気配	1.62
出来高	979,453
平均出来高（20日）	1,355,235
始値	1.59
前日終値	1.55
当日レンジ	1.54 - 1.60
52週レンジ	1.07 - 6.17
アナリスト	n/a
目標株価	n/a
配当	n/a
権利落ち日	n/a

ALDXについて

Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. T...

[続きを読む]

業種 Biotechnology

セクター Healthcare

IPO日 May 2, 2014

従業員数 6

上場取引所 NasdaqCM

ティッカー ALDX

ウェブサイト https://www.aldeyra.com

企業情報の全文

業績

2025年のAldeyra Therapeuticsの売上高は0で、前年の0からundefined%の増加でした。利益は-33.85Mで、-39.4%の減少でした。

財務諸表

決算サプライズ

Aldeyra TherapeuticsはAug 6, 2026に四半期決算を発表しました：

売上高は $0 で、予想を下回りました $0, うち NaN% の前年比増加にあたります.

EPSは -0.09 で、予想を下回りました -0.01, うち 43.75% の前年比増加にあたります.

次回決算発表

Aldeyra Therapeutics Inc.の決算発表予定日は Nov 4, 2026, 取引時間中の予定です。
アナリストの売上高予想は ... アップグレード

ニュース

2か月前 · Simply Wall St.

CEO, President & Director of Aldeyra Therapeutics Picks Up 18% More Stock

Investors who take an interest in Aldeyra Therapeutics, Inc. ( NASDAQ:ALDX ) should definitely note that the CEO...

2か月前 · MarketBeat

Aldeyra Therapeutics Eyes FDA Feedback as Dry Eye Drug Faces Make-or-Break Moment

Aldeyra Therapeutics (NASDAQ:ALDX) Chief Executive Todd Brady said the company expects near-term feedback from the U.S. Food and Drug Administration on its dry eye disease candidate reproxalap, follow...

2か月前 · Simply Wall St.

3 Promising Penny Stocks With Market Caps Reaching $300M

The market remained flat over the last week, but it is up 26% over the past year, with earnings forecast to grow by 17% annually. Investing in penny stocks—once a buzzword but now more of a niche—can ...

3か月前 · Simply Wall St.

Upstart Holdings Leads These 3 Stocks Estimated To Be Trading Below Fair Value

Over the last 7 days, the United States market has risen by 1.1%, and over the past 12 months, it is up by an impressive 27%, with earnings expected to grow by 17% per annum in the coming years. In th...

3か月前 · Simply Wall St.

3 Stocks That May Be Undervalued According To Analysts In May 2026

Over the last 7 days, the United States market has risen by 1.1%, contributing to a remarkable 27% climb over the past year, with earnings forecasted to grow by 17% annually. In this thriving environm...

2ページ中1ページ

Aldeyra Therapeutics Inc. (ALDX)